Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Accounts Payables (2017 - 2025)

Crinetics Pharmaceuticals has reported Accounts Payables over the past 9 years, most recently at $41.8 million for Q4 2025.

  • Quarterly results put Accounts Payables at $41.8 million for Q4 2025, up 94.56% from a year ago — trailing twelve months through Dec 2025 was $41.8 million (up 94.56% YoY), and the annual figure for FY2025 was $41.8 million, up 94.56%.
  • Accounts Payables for Q4 2025 was $41.8 million at Crinetics Pharmaceuticals, up from $33.7 million in the prior quarter.
  • Over the last five years, Accounts Payables for CRNX hit a ceiling of $41.8 million in Q4 2025 and a floor of $3.4 million in Q4 2021.
  • Median Accounts Payables over the past 5 years was $11.0 million (2022), compared with a mean of $15.8 million.
  • Biggest five-year swings in Accounts Payables: tumbled 77.48% in 2024 and later skyrocketed 581.8% in 2025.
  • Crinetics Pharmaceuticals' Accounts Payables stood at $3.4 million in 2021, then surged by 348.6% to $15.4 million in 2022, then soared by 51.1% to $23.2 million in 2023, then dropped by 7.45% to $21.5 million in 2024, then soared by 94.56% to $41.8 million in 2025.
  • The last three reported values for Accounts Payables were $41.8 million (Q4 2025), $33.7 million (Q3 2025), and $38.1 million (Q2 2025) per Business Quant data.